Loading…
Sectoral / Thematic · Nippon India Mutual Fund · AMFI code 102431Nippon India Pharma Fund
Disclosed for 84 months, Sep 2019 to Aug 2026.Published as: NIPPON INDIA PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹2,332 Cr
Sep 2019
- Stocks held
- 18
- Top 10 weight
- 78.3%
- of the portfolio in its ten largest
- Cash & debt
Nippon India Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In September 2019 it disclosed 18 stocks worth ₹2,332 Cr. Its largest positions were Sun Pharmaceutical Industries Limited (10.9%), Divi's Laboratories Limited (10.7%), Aurobindo Pharma Limited (8.3%); the ten largest together made up 78.3% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 78.9% of its equity. Cash and debt stood at 0.2%.
Against 229 other Sectoral / Thematic funds
Concentration
97%
Top-10 weight is higher than 97% of peers
Breadth
5%
Holds more stocks than 5% of peers
Cash
3%
Holds more cash than 3% of peers
What these mean: concentration · cash
Holdings in September 2019
Download CSVEvery line the fund disclosed, with the change against the previous month. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 10.86% | — | ₹253 Cr | — | |
| Divi's Laboratories Limited | 10.71% | — | ₹250 Cr | — | |
| Aurobindo Pharma Limited | 8.34% | — | ₹194 Cr | — | |
| Cipla Limited | 7.85% | — | ₹183 Cr | — | |
| Dr. Reddy's Laboratories Limited | 7.53% | — | ₹176 Cr | — | |
| Abbott India Limited | 7.13% | — | ₹166 Cr | — | |
| Lupin Limited | 7.06% | — | ₹165 Cr | — | |
| Syngene International Limited | 6.67% | — | ₹156 Cr | — | |
| Fortis Healthcare Limited | 6.61% | — | ₹154 Cr | — | |
| Alkem Laboratories Limited | 5.51% | — | ₹129 Cr | — | |
| Biocon Limited | 5.17% | — | ₹121 Cr | — | |
| Sanofi India Limited | 5.04% | — | ₹118 Cr | — | |
| Thyrocare Technologies Limited | 4.89% | — | ₹114 Cr | — | |
| Zydus Lifesciences Limited | 2.53% | — | ₹58.9 Cr | — | |
| Narayana Hrudayalaya Limited | 1.63% | — | ₹38.1 Cr | — | |
| FDC Limited | 1.05% | — | ₹24.4 Cr | — | |
| Indoco Remedies Limited | 0.70% | — | ₹16.4 Cr | — | |
| Healthcare Global Enterprises Limited | 0.50% | — | ₹11.6 Cr | — | |
| Cash, TREPS & receivables | 0.22% | — | ₹5.1 Cr | — |
What changed
This is the earliest month on record for the fund.
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
No earlier month with a sector split to compare against.
Allocation in Sep 2019
- Pharmaceuticals & Biotechnology (12)78.9%
- Healthcare Services (5)20.3%
- Pharmaceuticals (1)0.7%
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Sep 2019
0.2%
- Cash alone
- 0.2%
- cash and net receivables
- A year earlier
- —
- no disclosure
- Last 12 months
- —
- lowest to highest · record 0.2% in Sep 2019
Not enough months to draw.
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.